In phase 3 trials, Pfizer and BioNTech's vaccine showed strong immune responses against influenza A and COVID-19 but failed to meet key objectives for influenza B....
BioNTech 's turnover in 2022 was €17.31 billion, which represented a decrease of 8.8%. By business segments, those from the marketing of medicines amounted to €17.2...